Increased production of tumor necrosis factor ␣ (TNF) in the bone marrow (BM) in response to both oxidative stress and T cell activation contributes to the bone loss induced by estrogen deficiency, but it is presently unknown whether oxidative stress causes bone loss through T cells. Here we show that ovariectomy causes an accumulation in the BM of reactive oxygen species, which leads to increased production of TNF by activated T cells through upregulation of the costimulatory molecule CD80 on dendritic cells. Accordingly, bone loss is prevented by treatment of ovariectomized mice with either antioxidants or CTLA4-Ig, an inhibitor of the CD80/CD28 pathway. In summary, reactive oxygen species accumulation in the BM is an upstream consequence of ovariectomy that leads to bone loss by activating T cells through enhanced activity of BM dendritic cells, and these findings suggest that the CD80/CD28 pathway may represent a therapeutic target for postmenopausal bone loss.
Increased production of tumor necrosis factor ␣ (TNF) in the bone marrow (BM) in response to both oxidative stress and T cell activation contributes to the bone loss induced by estrogen deficiency, but it is presently unknown whether oxidative stress causes bone loss through T cells. Here we show that ovariectomy causes an accumulation in the BM of reactive oxygen species, which leads to increased production of TNF by activated T cells through upregulation of the costimulatory molecule CD80 on dendritic cells. Accordingly, bone loss is prevented by treatment of ovariectomized mice with either antioxidants or CTLA4-Ig, an inhibitor of the CD80/CD28 pathway. In summary, reactive oxygen species accumulation in the BM is an upstream consequence of ovariectomy that leads to bone loss by activating T cells through enhanced activity of BM dendritic cells, and these findings suggest that the CD80/CD28 pathway may represent a therapeutic target for postmenopausal bone loss.
CTLA-4Ig ͉ reactive oxygen species ͉ T cells ͉ osteoporosis ͉ tumor necrosis factor P ostmenopausal bone loss is induced by ovarian involution and the resulting increase in follicle-stimulating hormone production through multiple effects on bone marrow (BM) and bone cells (1) (2) (3) (4) , but the most relevant consequence of natural menopause and ovariectomy (ovx) is a cytokine-driven increase in osteoclast (OC) formation (2, 4) . OC formation occurs when bone marrow macrophages (BMMs) are costimulated by the essential osteoclastogenic factors receptor activator of nuclear factor-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) (2), but after menopause TNF is produced in greater amounts in the BM and up-regulates OC formation (4, 5) . TNF stimulates the production of RANKL and M-CSF by bone and BM cells (6, 7) , augments the responsiveness of OC precursors to RANKL (8, 9) , and induces additional osteoclastogenic cytokines such as IL-1, IL-6, and IL-7 (4). Studies with genetic and pharmacological models have demonstrated the pivotal role of TNF in ovx-induced bone loss in rodents and humans (10) (11) (12) (13) and have provided insights on the estrogen (E)-regulated sources of TNF. Ovx upregulates the production of TNF by BM T lymphocytes (8, 12) by increasing thymic T cell output (14) and by stimulating the antigen (Ag)-dependent activation and expansion of T cells in the BM (15) . Attesting to the relevance of T cell-produced TNF, T cell-deficient nude mice are protected against the loss of cortical and trabecular bone induced by ovx (8, 12, 16) . Furthermore, the capacity of ovx to induce bone loss is restored by adoptive transfer into nude mice of T cells from wild-type (WT) but not of those from TNF Ϫ/Ϫ mice (12) .
T cell activation is caused by the presentation to T cells of Ag fragments bound to MHC molecules expressed on Ag-presenting cells (APCs) (17) . Ovx up-regulates the capacity of BMMs to present Ag to CD4ϩ T cells (4, 15) , but no information is available on how ovx activates CD8ϩ T cells and on whether ovx has additional stimulatory effects on BM DCs, the most potent professional APCs residing in the BM (18) .
Ovx alters the generation of ROS and the antioxidant defense capacity of the cell (19, 20) , leading to an accumulation of ROS, which stimulate the production of TNF in the BM. This effect is compounded by the capacity of ROS to stimulate OC formation and activity directly (20) (21) (22) . However, little information is available regarding the cell lineage that produces TNF in response to ROS (19) .
Because ROS activate Ag presentation by DCs (23) and activated T cells further stimulate Ag presentation by BMMs through production of IFN␥, a plausible hypothesis, tested herein is that ovx induces the activation of both CD4ϩ and CD8ϩ cells through ROS-mediated stimulation of Ag presentation by DCs. We show that the generation of ROS represents an ''upstream'' event that leads to bone loss by increasing the capacity of DCs to present Ag, thus promoting the production of TNF by activated T cells.
Results

Ovx Selectively Activates BM DCs Through Increased Costimulation by
CD80.
To assess the effects of ovx on the number and function of APCs, BM was harvested 2 weeks after sham operation or ovx, a time when the rate of bone loss is most rapid (8, 12, 16) . Ovx did not alter the percentage of DCs (data not shown) nor that of DCs expressing MHCII (Fig. 1A) , whereas it increased the percentage of DCs expressing CD80, a costimulatory molecule that binds to the T cell receptor CD28 (17) . Confirming earlier reports (15) , ovx caused a 2-fold increase in the total number of BMMs and BM B cells (data not shown). The total number of BM DCs was also Ϸ50% higher in ovx mice than in sham controls (Fig. 1B) . Ovx caused only a small increase in the number of MHCIIϩ DCs, whereas the number of DCs expressing CD80 was Ϸ3.5-fold higher in ovx than in sham mice. Attesting to specificity, ovx did not affect the expression of the DC costimulatory molecules CD86, CD40, PDL-1, PDL-2, and OX40 (data not shown). Characterization studies of BM DCs revealed that ovx increased the percentage of both CD80ϩ plasmacytoid (B220ϩ) DCs, and CD80ϩCD8Ϫ conventional (B220Ϫ) DCs, but not that of CD80ϩCD8ϩB220Ϫ DCs [supporting information (SI) Fig. 5 ]. Furthermore, ovx did not alter the percentage of any CD80Ϫ DC lineage. Ref lecting the generalized increase in BM cellularity induced by ovx, the total number of most BM DC subsets was higher in ovx than in sham mice (SI Table 2 ). However, the increase induced by ovx was larger for CD80ϩ conventional DCs than for the other DC lineage.
Ovx increased Ag presentation by BMMs and BM DCs by Ϸ2-and Ϸ5-fold, respectively (Fig. 1C) . The effect of ovx on DCs was organ-specific because ovx increased the activity of BM DCs, but it failed to affect that of spleen and lymph node DCs (Fig. 1D) .
The expression of class II transactivator (CIITA), a gene that encodes for a nuclear activator of MHCII transcription, is characteristically down-regulated as DCs acquire the capacity to present Ag (24) . Attesting to an effect of ovx on DC activation, we found ovx to decrease the expression of CIITA mRNA by BM DC by Ϸ60% (Fig. 1E) . Analysis of the T cell activation marker CD69 at 2 weeks revealed that ovx increases CD69 expression on BM CD4ϩ (Fig. 1F ) and CD8ϩ T cells (Fig. 1G) but not in spleen T cells. Thus, the activation of DCs coincides, both spatially and temporally, with the activation of T cells.
To assess whether T cell TNF production coincides with DC activation, we cocultured ␥-irradiated BM and spleen DCs from sham and ovx mice with the avian Ag ovalbumin and T cells from OT-II mice, a strain with T cells that harbor a transgenic T cell receptor responsive exclusively to ovalbumin. In this model ovalbumin-derived peptides presented by APCs to T cells induce T cell activation and T cell cytokine secretion. TNF was measured in the culture medium at the end of a 3-day culture period. Ovx increased the production of TNF by Ϸ40% in cocultures containing BM DC, whereas it had no effects in those containing spleen DCs (Fig. 1H) .
Together, the data demonstrate that increased Ag presentation by BM DCs leads to T cell activation and T cell TNF production.
Ovx Induces a Tissue-Selective Increase in Oxidative Stress in the BM.
Oxidative stress has been implicated in ovx-induced bone loss (19, 20, 22) , although how ovx increases oxidative stress is unknown. To address this issue we measured the levels of APE-1/Ref-1, peroxiredoxin-1 (Prx-1), and glutathione (GSH) in BM, spleen, and liver. These two latter tissues were chosen as controls because they are known active sites of ROS production both under physiological and pathological conditions (25) (26) (27) . APE-1/Ref-1 is an inhibitor of the NADPH oxidase that regulates the intracellular generation of ROS (28) and is also a redox coactivator of NF-B (29) . Prx-1 provides cytoprotection against cellular oxidative stress through its thioredoxin-dependent peroxidase activity (30) , whereas GSH is essential to eliminate intracellular peroxide (31) .
In the BM, ovx induced a 4-fold decrease in intracellular APE-1/Ref-1 ( Fig. 2A) , a nearly 3-fold decrease in Prx-1 levels (Fig. 2B) , and a 30% decrease in intracellular GSH ( Protein carbonyl formation is a consequence of oxidative damage to cellular proteins (32) . Thus, protein carbonylation was quantified in the BM to determine the extent of oxidative damage and was found to be significantly increased by ovx (Fig. 2D) . Therefore, ovx induces a tissue-selective decrease in both ROS intracellular scavengers and inhibitors of ROS generation, leading to a local accumulation of ROS-induced protein damage in the BM.
Antioxidants Prevent the Activation of BM DCs and T Cells Induced by
Ovx. One relevant consequence of increased ROS production is induction of APC maturation and T cell activation (23, 33) . We thus investigated whether ovx increases Ag presentation by DCs, T cell activation, and T cell TNF production, through oxidative stress. First, we assessed whether CD80 expression is directly modulated by ROS. Thus, BM from intact mice was treated in vitro with hydrogen peroxide (H 2 O 2 ) for 24 h to increase the levels of ROS. Measurements of cell viability by trypan blue exclusion showed the viability of BM cells to be Ͼ90% and Ͼ75% after treatment with H 2 O 2 at 100 nM and 1,000 nM, respectively. FACS analysis of gated MHCII hi cells, a population of mature APCs, revealed that H 2 O 2 caused a dose-dependent expansion of the pool of CD80ϩCD11cϩ cells (Fig. 2E ) and an increase in CD4 and CD8 T cell activation (Fig. 2F) . These findings suggest that CD80-dependent T cell costimulation is up-regulated by ROS.
To determine whether ovx activates T cells through oxidative stress in vivo, ovx mice were treated for 4 weeks with N-acetylcysteine (NAC), an antioxidant that restores the intracellular pool of GSH, preventing increases in ROS. Measurements of GSH levels in the BM confirmed that NAC completely prevented the decrease in GSH levels induced by ovx (data not shown). Furthermore, NAC prevented the increase in Ag presentation by BM DCs (Fig. 3A) , the increase in the relative number of CD80ϩ BM DCs (Fig. 3B) , increases in the total number of BM CD69ϩCD4ϩ (Fig. 3C) and CD69ϩCD8ϩ T cells (Fig. 3D) , and the increase in TNF production by ex vivo cultures of BM (Fig. 3E) .
Furthermore, in vivo measurement of bone mineral density by dual-energy x-ray absorptiometry (DXA), a technique that provides a combined assessment of cortical and trabecular bone, revealed that NAC treatment decreased the femoral bone loss induced by ovx (Fig. 3F) . Ex vivo micro-computed tomography (CT) measurements of vertebral trabecular bone, the skeletal site most affected by ovx, demonstrated that NAC prevents the loss of trabecular bone induced by ovx (Fig. 3G) . Thus, the ovx-induced accumulation of ROS in BM stimulates immune cell activation and TNF production, whereas antioxidants prevent ovx-induced bone loss.
CTLA4-Ig Blocks Costimulation by CD80 Receptor and Protects Mice
from Ovx-induced Bone Loss. Up-regulation of CD80 expression on APCs and its binding to CD28 on T cells is one of the earliest events in Ag-dependent T cell activation (17) . To test the relevance of CD80-mediated T cell activation on ovx-induced bone loss, mice were treated with 500 g/day CTLA4-Ig, an immunosuppressant that inhibits the binding of CD80 (and CD86) to CD28, or 500 g/day irrelevant (Irr) isotype-matched Ig. In a first experiment, mice were treated with CTLA4-Ig or Irr-Ig three times a week for 4 weeks. CTLA4-Ig prevented the increase in the number of CD4ϩCD69ϩ and CD8ϩCD69ϩ BM T cells (Fig. 4 A and B) as well as the increase in T cell TNF production induced by ovx (Fig.  4C) , confirming that ovx activates T cells through Ag presentation. Measurements of serum C-terminal telopeptides (CTX), a marker of bone resorption (Fig. 4D) , and serum osteocalcin, a marker of formation (Fig. 4E) , revealed that the increase in both indices induced by ovx was prevented by CTLA4-Ig.
To investigate the effect of CTLA4-Ig on in vitro OC formation, whole BM was cultured in the presence of a suboptimal concentration of RANKL. BM from ovx mice generated a 2-fold higher number of OCs than BM from sham controls (Fig. 4F) , and the ovx-induced increase in OC formation was prevented by in vivo CTLA4-Ig treatment. In vitro treatment of osteoclastogenic cultures of BMMs with CTLA4-Ig did not alter the production of mature OCs (data not shown), demonstrating that CTLA4-Ig inhibits OC formation in vivo without directly inhibiting OC differentiation.
In vivo prospective measurements of femoral bone mineral density by DXA showed (Fig. 4G ) that CTLA4-Ig completely prevented the femoral bone loss induced by ovx. CT measurements of femoral trabecular bone harvested at 4 weeks showed (Fig.  4H ) that treatment with CTLA4-Ig afforded nearly complete protection against the loss of trabecular bone volume and trabecular thickness induced by ovx. Analysis of trabecular bone by histomorphometry (Table 1) confirmed that treatment with CTLA4-Ig prevents the loss of trabecular bone volume induced by ovx as well as the increase in bone resorption, as assessed by measurements of the number of OCs per bone surface and the percent eroded surfaces. Treatment with CTLA4-Ig also prevented the ovx-induced increase in the percent of bone surface covered by osteoid and the percent of bone surface covered by osteoblasts, two indices of bone formation.
In a second set of experiments, CTLA4-Ig was injected during the 1st week after surgery and then discontinued, a protocol that ensures high circulating levels of the drug until the end of the 2nd week of follow-up (34). Subsets of mice were then killed at 2 and 4 weeks from surgery. In vivo bone density measurements by DXA as well as ex vivo CT analysis of femurs showed a significant protection against ovx-induced bone loss by CTLA4-Ig treatment at 2 weeks. However, at 4 weeks, CTLA4-Ig-treated mice showed values of bone density similar to Irr-Ig-treated ovx mice, indicating that bone loss had resumed (SI Fig. 7) .
Discussion
Among the mechanisms responsible for ovx-induced bone loss is an expansion of the pool of activated T cells that produce TNF (8, 12) . Ovx increases CD4ϩ T cell activation by enhancing Ag presentation by BMMs through increased expression of MHCII, a phenomenon caused by a complex mechanism that involves increased production of IFN␥ and IL-7 and blunted generation of TGF␤ in the BM (15, 16, 35, 36) . Here we show that additional effects of ovx are to expand the pool of BM plasmacytoid and conventional mature DCs and to enhance Ag presentation by BM DCs through up-regulation of the costimulatory molecule CD80. The latter leads to the activation in the BM of both CD4ϩ and CD8ϩ T cells. DCs are the most potent professional APCs (18) , and ovx increases their antigen-presenting activity by Ϸ5-fold, whereas it enhances that of BMMs by Ϸ2-fold (15) . Therefore, DCs play a pivotal role in the T cell activation induced by ovx.
A striking finding of this work is that ovx activates BM DCs without affecting DCs localized in other secondary lymphoid organs, a phenomenon that may explain why E deprivation triggers an effector T cell response in the BM but does not induce a systemic inflammatory and/or immune response. Accordingly, an effect of ovx on DCs was not demonstrated in an earlier study (15) because only DCs derived from lymph nodes were analyzed.
Our findings demonstrate that a mechanism by which ovx elicits a tissue-specific DC response is a change in redox state, a key microenvironment determinant (21) . Multiple enzymatic pathways regulate the intracellular redox state through modulation of ROS levels (37) . Ovx blunts the BM levels of GSH, a critical ROS scavenger, and those of APE-1/Ref-1 and Prx-1, proteins that contribute to limit the production of intracellular ROS (28) . Furthermore, the finding in the BM of ovx mice of increased protein carbonylation, a marker of protein oxidation (32) , attests to the functional relevance of the ovx-induced oxidative stress. Like the activation of DCs, the effects of ovx on the redox state are spatially limited to the BM a phenomenon noted previously by Lean et al. (19) .
ROS comprise the superoxide anion (O 2 Ϫ ⅐ ), which has a short half-life and is an intermediate during the reduction of molecular oxygen to H 2 O 2 . The latter is the most abundant and long-lasting ROS. H 2 O 2 plays a critical role in inflammation through its direct effects or by its transformation into OH ⅐ (38). This OH ⅐ is a more potent ROS than H 2 O 2 but exerts its effects only locally because of its short half-life. Because ovx decreases Prx-1 and GSH levels, the data suggest that ovx increases H 2 O 2 levels (30). The finding of an increase in protein carbonylation further suggests that a free radical process was involved. However, because we did not measure specific oxidant species, a contribution of other reactive oxygen species such as O 2 Ϫ ⅐ and of Prx-1 cannot be excluded. Reports have suggested that stimulation of TNF production by OCs or BM cells is the mechanism by which ROS cause bone loss (19, 20, 39) . However these studies did not provide conclusive information regarding the cellular source of TNF nor about the mechanisms by which ROS stimulates TNF production. The current work demonstrates that key effects of ovx, the up-regulation of Ag-dependent activation of T cells and the resulting T cell production of TNF, are mediated by ROS and abolished by treatment with antioxidants. We also found that oxidative stress, like ovx, causes an expansion of mature CD80ϩDCs and that antioxidants prevent the increase in the number of CD80ϩDCs and the bone loss induced by ovx. Together, these data suggest that the accumulation of ROS in the BM is the upstream event that leads to a tissue-specific activation of DCs and T cell-dependent overproduction of TNF.
The interaction of activated T cells with immature DCs in areas of inflammation is now known to promote the transdifferentiation of DCs into OCs (40, 41) . Because ovx causes an increase in the number of several populations of BM DCs, the up-regulation of osteoclastogenesis induced by ovx is likely to be due, in part, to the transdifferentiation of immature DCs. However, the finding that ovx increases the percentage of CD80ϩ DCs but not that of immature (CD80Ϫ) DCs suggests that in ovx mice DCs stimulate OC formation primarily by increasing Ag presentation and T cell activation.
In the context of Ag recognition, the interaction of the costimulatory molecule CD80 on APCs with the T cell-expressed receptor CD28 is required for T cell activation. CTLA4-Ig is a fusion protein that promotes T cell anergy and apoptosis by binding to CD80 (and CD86) and blocking their interaction with CD28 (42, 43) . We found that in vivo treatment with CTLA4-Ig prevents the increase in T cell activation and proliferation and TNF production resulting from E withdrawal, and it affords considerable protection against ovxinduced bone loss. Furthermore, because CTLA4-Ig does not directly target OCs and does not block the direct effects of ROS on OC maturation, the data argue against the hypothesis proposed by others that ROS induce bone loss primarily by directly promoting OC differentiation and/or by stimulating mature OCs to secrete TNF (19) .
The bone-sparing activity of CTLA4-Ig demonstrates that activated T cells play a pivotal causal role in the mechanism by which ovx causes bone loss in WT mice. Thus, the current work provides confirmation in WT mice of previous reports demonstrating that ovx fails to induce trabecular and cortical bone loss in T celldeficient nude mice (8, 12, 16) . In contrast, another study (44) showed that nude mice lose trabecular bone after ovx, although they are protected against the loss of cortical bone. In the same investigation, ovx was found not to induce cortical bone loss in either the spine or the femur in TCR␣ Ϫ/Ϫ and RAG2 Ϫ/Ϫ mice, although it induced trabecular bone loss in both strains. The partially negative outcome of that study is likely explained by age and experimental design differences, the presence of residual T cells in some strains, and by ovx-independent alterations of bone resorption induced by either the concomitant lack of B cells or genetic compensations.
In summary, our data reveal that induction of oxidative stress is a localized upstream consequence of acute E deprivation, which leads to Ag-dependent activation of T cells through up-regulation of the costimulatory molecule CD80 on DCs. The downstream consequence of these events is increased T cell TNF production and bone loss. The capacity of CTLA4-Ig to prevent ovx-induced bone loss confirms the role of activated T cells in the bone-wasting effect of E deficiency and suggests that the CD80/CD28 pathway may represent a therapeutic target for postmenopausal bone loss.
Materials and Methods
Animal Protocol. All animal procedures were approved by the Institutional Animal Care and Use Committee of Emory University. Female C57BL/6 WT mice were sham operated or ovariectomized at 14 weeks of age, and killed 2-4 weeks later. At sacrifice, one femur and lumbar vertebra were excised for histomorphometric and CT analysis, and BM was harvested from the remaining bones for ex vivo analysis. Uterine weight was determined at death to verify successful ovx.
CTLA4-Ig and NAC Treatment. Mice (n ϭ 7-8 per group) were injected i.p. with CTLA4-Ig or isotype-matched Irr human IgG, (500 g of each per mouse, three times a week) for either 2 or 4 weeks, starting the day before surgery. In another set of experiments mice (n ϭ 7 per group) were injected i.p. with NAC at 100 g/kg per day, or vehicle, twice a day for 4 weeks.
Bone Mineral Density (BMD) Measurements. Femoral BMD was measured in anesthetized mice at 0, 2, and 4 weeks by using a PIXImus2 bone densitometer as described previously (14) (15) (16) . This technique provides a combined measurement of cortical and trabecular bone. The short-term reproducibility of this technique is 1.7% (45).
CT Analysis. The distal femoral epiphysis and vertebrae were analyzed at sacrifice by using a CT 40 scanner (Scanco Medical, Bassersdorf, Switzerland) at a resolution of 12 m, as described previously (36, 46) . Femoral histomorphometric indices were calculated by using 40 slices proximal to the growth plate (480 m total length) with the Image Processing Language package provided by the manufacturer. Vertebral indices were calculated by analyzing 30 slices of the L4 vertebra and by measuring three-dimensional distances directly in the trabecular network.
Quantitative Bone Histomorphometry. Bone histomorphometry was performed as described previously (8, 10) at the University of Alabama at Birmingham Center for Metabolic Bone DiseaseHistomorphometry and Molecular Analysis Core Laboratory. The measurements, terminology, and units used for histomorphometric analysis were those recommended by the Nomenclature Committee of the American Society of Bone and Mineral Research (47) . Analysis of the epiphyseal region of the distal femur was performed by using trichrome-stained, plastic-embedded sections. were measured by Western blotting on samples (n ϭ 3 mice per group) collected at 4 weeks from surgery as described (48) with anti-APE-1/Ref-1 mAb or with polyclonal anti-Prx1 Ab followed by secondary Ab conjugated to horseradish peroxidase. Blots were developed by using the ECL chemiluminescence procedure. GSH was measured by HPLC as described (31) . Briefly, GSH was converted to N-dansyl,S-carboxymethyl-GSH and quantified relative to an internal standard (␥-glutamylglutamate) by HPLC with fluorescence detection.
Protein Carbonylation. Measurements of carbonyl formation were carried out by using the OxyBlot protein oxidation detection kit WT mice were treated with CTLA4-Ig or isotype-matched Irr-Ig (500 g per day of each) three times a week for 4 weeks, and femurs were analyzed by histomorphometry. BV/TV (the percentage of total volume occupied by trabecular bone volume) is an index of bone structure. N.OC/BS (the no. of osteoclasts per mm of bone surface), and ES/BS (the percentage of eroded surfaces) are indices of bone resorption. OS/BS (the percentage of bone surface covered by osteoid) and ObS/BS (the percentage of bone surface covered by osteoblasts) are indices of bone formation. Data are expressed as mean Ϯ SEM. * , P Ͻ 0.05 compared with sham Irr-Ig-treated mice.
